Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Liabilities and Shareholders Equity (2016 - 2025)

Tvardi Therapeutics' Liabilities and Shareholders Equity history spans 13 years, with the latest figure at $32.1 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 8.88% to $32.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $153.8 million, a 38.27% decrease, with the full-year FY2025 number at $32.1 million, down 8.88% from a year prior.
  • Liabilities and Shareholders Equity hit $32.1 million in Q4 2025 for Tvardi Therapeutics, down from $39.0 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for TVRD hit a ceiling of $250.2 million in Q1 2021 and a floor of $32.1 million in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $136.1 million across 5 years, with a median of $130.1 million in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 52.98% in 2021 and later crashed 72.03% in 2024.
  • Tracing TVRD's Liabilities and Shareholders Equity over 5 years: stood at $247.1 million in 2021, then dropped by 26.24% to $182.2 million in 2022, then tumbled by 30.94% to $125.8 million in 2023, then crashed by 72.03% to $35.2 million in 2024, then fell by 8.88% to $32.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for TVRD at $32.1 million in Q4 2025, $39.0 million in Q3 2025, and $43.8 million in Q2 2025.